Complementary molecular approaches reveal heterogeneous CDH1 germline defects in Italian patients with hereditary diffuse gastric cancer (HDGC) syndrome

Valeria Molinaro, Valeria Pensotti, Monica Marabelli, Irene Feroce, Monica Barile, Simonetta Pozzi, Luigi Laghi, Davide Serrano, Loris Bernard, Bernardo Bonanni, Guglielmina Nadia Ranzani

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Germline inactivation of the E-cadherin gene (CDH1) is associated with hereditary diffuse gastric cancer (HDGC), a rare autosomal dominant syndrome predisposing to both diffuse gastric cancer (DGC) and lobular breast cancer (LBC). We searched for CDH1 germline defects in 32 HDGC Italian probands selected according to international consensus criteria and in 5 selected relatives. We used a series of molecular methods, including: DNA sequencing, multiplex ligation-dependent probe amplification, single-nucleotide primer extension, bisulfite sequencing, reverse-transcription PCR, and bioinformatics tools. We identified pathogenic mutations in 6 out of 32 probands (19%): one truncating and two missense mutations, one large deletion, one allelic expression imbalance and one splicing defect. Three out of six CDH1 constitutive alterations were novel. Our data support the need for a multimethod approach for CDH1 genetic testing, demonstrating that both DNA and RNA analyses are required to increase the detection rate of pathogenic mutations, thus reducing the number of patients without a clear molecular diagnosis. On the whole, our results indicate that not only DGC patients, but also subjects with personal or family history of LBC might benefit from CDH1 genetic testing. Moreover, our findings support the notion that prophylactic gastrectomy should be offered to asymptomatic CDH1 mutation carriers; indeed, while endoscopic analysis with histological examination of random gastric biopsies can miss cancer foci, gastrectomy performed in these subjects always revealed foci of cancer cells.

Original languageEnglish
Pages (from-to)432-445
Number of pages14
JournalGenes Chromosomes and Cancer
Volume53
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Stomach Neoplasms
Genetic Testing
Gastrectomy
Breast Neoplasms
Allelic Imbalance
Mutation
Multiplex Polymerase Chain Reaction
Mutation Rate
Missense Mutation
Cadherins
Computational Biology
DNA Sequence Analysis
Reverse Transcription
Neoplasms
Stomach
Consensus
Nucleotides
RNA
Biopsy
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Complementary molecular approaches reveal heterogeneous CDH1 germline defects in Italian patients with hereditary diffuse gastric cancer (HDGC) syndrome. / Molinaro, Valeria; Pensotti, Valeria; Marabelli, Monica; Feroce, Irene; Barile, Monica; Pozzi, Simonetta; Laghi, Luigi; Serrano, Davide; Bernard, Loris; Bonanni, Bernardo; Ranzani, Guglielmina Nadia.

In: Genes Chromosomes and Cancer, Vol. 53, No. 5, 2014, p. 432-445.

Research output: Contribution to journalArticle

@article{5f3105166dfb4cf2ab2f10c09c9dbede,
title = "Complementary molecular approaches reveal heterogeneous CDH1 germline defects in Italian patients with hereditary diffuse gastric cancer (HDGC) syndrome",
abstract = "Germline inactivation of the E-cadherin gene (CDH1) is associated with hereditary diffuse gastric cancer (HDGC), a rare autosomal dominant syndrome predisposing to both diffuse gastric cancer (DGC) and lobular breast cancer (LBC). We searched for CDH1 germline defects in 32 HDGC Italian probands selected according to international consensus criteria and in 5 selected relatives. We used a series of molecular methods, including: DNA sequencing, multiplex ligation-dependent probe amplification, single-nucleotide primer extension, bisulfite sequencing, reverse-transcription PCR, and bioinformatics tools. We identified pathogenic mutations in 6 out of 32 probands (19{\%}): one truncating and two missense mutations, one large deletion, one allelic expression imbalance and one splicing defect. Three out of six CDH1 constitutive alterations were novel. Our data support the need for a multimethod approach for CDH1 genetic testing, demonstrating that both DNA and RNA analyses are required to increase the detection rate of pathogenic mutations, thus reducing the number of patients without a clear molecular diagnosis. On the whole, our results indicate that not only DGC patients, but also subjects with personal or family history of LBC might benefit from CDH1 genetic testing. Moreover, our findings support the notion that prophylactic gastrectomy should be offered to asymptomatic CDH1 mutation carriers; indeed, while endoscopic analysis with histological examination of random gastric biopsies can miss cancer foci, gastrectomy performed in these subjects always revealed foci of cancer cells.",
author = "Valeria Molinaro and Valeria Pensotti and Monica Marabelli and Irene Feroce and Monica Barile and Simonetta Pozzi and Luigi Laghi and Davide Serrano and Loris Bernard and Bernardo Bonanni and Ranzani, {Guglielmina Nadia}",
year = "2014",
doi = "10.1002/gcc.22155",
language = "English",
volume = "53",
pages = "432--445",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Complementary molecular approaches reveal heterogeneous CDH1 germline defects in Italian patients with hereditary diffuse gastric cancer (HDGC) syndrome

AU - Molinaro, Valeria

AU - Pensotti, Valeria

AU - Marabelli, Monica

AU - Feroce, Irene

AU - Barile, Monica

AU - Pozzi, Simonetta

AU - Laghi, Luigi

AU - Serrano, Davide

AU - Bernard, Loris

AU - Bonanni, Bernardo

AU - Ranzani, Guglielmina Nadia

PY - 2014

Y1 - 2014

N2 - Germline inactivation of the E-cadherin gene (CDH1) is associated with hereditary diffuse gastric cancer (HDGC), a rare autosomal dominant syndrome predisposing to both diffuse gastric cancer (DGC) and lobular breast cancer (LBC). We searched for CDH1 germline defects in 32 HDGC Italian probands selected according to international consensus criteria and in 5 selected relatives. We used a series of molecular methods, including: DNA sequencing, multiplex ligation-dependent probe amplification, single-nucleotide primer extension, bisulfite sequencing, reverse-transcription PCR, and bioinformatics tools. We identified pathogenic mutations in 6 out of 32 probands (19%): one truncating and two missense mutations, one large deletion, one allelic expression imbalance and one splicing defect. Three out of six CDH1 constitutive alterations were novel. Our data support the need for a multimethod approach for CDH1 genetic testing, demonstrating that both DNA and RNA analyses are required to increase the detection rate of pathogenic mutations, thus reducing the number of patients without a clear molecular diagnosis. On the whole, our results indicate that not only DGC patients, but also subjects with personal or family history of LBC might benefit from CDH1 genetic testing. Moreover, our findings support the notion that prophylactic gastrectomy should be offered to asymptomatic CDH1 mutation carriers; indeed, while endoscopic analysis with histological examination of random gastric biopsies can miss cancer foci, gastrectomy performed in these subjects always revealed foci of cancer cells.

AB - Germline inactivation of the E-cadherin gene (CDH1) is associated with hereditary diffuse gastric cancer (HDGC), a rare autosomal dominant syndrome predisposing to both diffuse gastric cancer (DGC) and lobular breast cancer (LBC). We searched for CDH1 germline defects in 32 HDGC Italian probands selected according to international consensus criteria and in 5 selected relatives. We used a series of molecular methods, including: DNA sequencing, multiplex ligation-dependent probe amplification, single-nucleotide primer extension, bisulfite sequencing, reverse-transcription PCR, and bioinformatics tools. We identified pathogenic mutations in 6 out of 32 probands (19%): one truncating and two missense mutations, one large deletion, one allelic expression imbalance and one splicing defect. Three out of six CDH1 constitutive alterations were novel. Our data support the need for a multimethod approach for CDH1 genetic testing, demonstrating that both DNA and RNA analyses are required to increase the detection rate of pathogenic mutations, thus reducing the number of patients without a clear molecular diagnosis. On the whole, our results indicate that not only DGC patients, but also subjects with personal or family history of LBC might benefit from CDH1 genetic testing. Moreover, our findings support the notion that prophylactic gastrectomy should be offered to asymptomatic CDH1 mutation carriers; indeed, while endoscopic analysis with histological examination of random gastric biopsies can miss cancer foci, gastrectomy performed in these subjects always revealed foci of cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=84895929478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895929478&partnerID=8YFLogxK

U2 - 10.1002/gcc.22155

DO - 10.1002/gcc.22155

M3 - Article

C2 - 24493355

AN - SCOPUS:84895929478

VL - 53

SP - 432

EP - 445

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 5

ER -